NCT02134925 2025-09-10
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT01059786 2025-06-12
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT02465268 2025-01-14
ATTAC-II
University of Florida
Phase 2 Completed
NCT03180957 2024-06-28
RIDD
University of Oxford
Phase 2 Completed
NCT02258451 2023-11-24
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Completed
NCT02366728 2023-06-08
ELEVATE
Duke University
Phase 2 Completed
NCT02513329 2023-06-05
Stellate Ganglion Block (SGB) For Women for Breast Cancer
Northwestern University
Phase 2 Completed
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT03122301 2022-08-09
Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer
Northwestern University
Phase 2 Terminated
NCT03241810 2020-09-02
SHERBOC
Elevation Oncology
Phase 2 Terminated
NCT02258464 2020-08-10
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Terminated
NCT02705352 2020-03-09
5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Massachusetts Eye and Ear Infirmary
Phase 2 Completed
NCT02525718 2019-08-14
Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction
Northwestern University
Phase 2 Completed
NCT00854308 2017-03-31
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
Genentech, Inc.
Phase 2 Completed
NCT01205503 2016-02-24
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
University of Kentucky
Phase 2 Completed